

Amendments to the claims:

This listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

Claims 1-20 (canceled).

Claim 21 (currently amended) ~~The peptide or polypeptide of claim 3~~ A peptide or polypeptide comprising an Fv molecule, a construct thereof, a fragment of either, or a construct of a fragment having enhanced binding characteristics so as to bind selectively and/or specifically to a target cell in favor of other cells, wherein the binding selectivity or specificity is primarily determined by a first hypervariable region, and wherein the Fv is a scFv or a dsFv, and optionally having one or more tags, and wherein the binding selectivity or specificity is secondarily influenced by a second hypervariable region, by a third hypervariable region, and/or by one or more of the upstream or downstream region flanking the first, the second and/or the third hypervariable regions, and
wherein the second and third hypervariable regions are a CDR2 and CDR1 hypervariable region respectively and wherein the CDR3, CDR2 and CDR1 regions have the amino acid sequences SEQ ID NOs:8, 115 and 114, respectively.

Claims 22-41 (canceled).